The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) secretion is greatly enhanced after Roux-en-Y gastric bypass (RYGB). While intact GLP-1exerts its metabolic effects via the classical GLP-1 receptor (GLP-1R), proteolytic processing of circulating GLP-1 yields metabolites such as GLP-1(9-36)amide/GLP-1(28-36)amide, that exert similar effects independent of the classical GLP-1R. We investigated the hypothesis that GLP-1, acting via these metabolites or through its known receptor, is required for the beneficial effects of RYGB using two models of functional GLP-1 deficiency - α-gustducin-deficient (α-Gust (-/-)) mice, which exhibit attenuated nutrient-stimulated GLP-1 secretion, and GLP-1R-deficient mice. We show that the effect of RYGB to enhance glucose-stimulated GLP-1 secretion was greatly attenuated in α-Gust (-/-) mice. In both genetic models, RYGB reduced body weight and improved glucose homeostasis to levels observed in lean control mice. Therefore, GLP-1, acting through its classical GLP-1R or its bioactive metabolites, does not seem to be involved in the effects of RYGB on body weight and glucose homeostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationWeight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“and one of the most efficacious [3,4].”
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200111 · Cited by 1,791
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 2×
“-Gustducin is also coexpressed with GLP-1 in L-cells and has been implicated in GLP-1 secretion in response to extracellular glucose, bile acids, and fatty acids [25, 26].”
BackgroundSelf-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 2×
“Glp1r mice lack the classical GLP-1R and exhibit impaired glucose tolerance and impaired glucose-stimulated insulin secretion [32].”
BackgroundMethodSelf-citationGut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741 · cited 3×
“Third, administration of octreotide to patients after RYGB inhibits the secretion of GLP-1 (and other gut hormones), and also decreases satiety and increases food intake [5].”
BackgroundLaferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682 · cited 2×
“, calorie restriction and restrictive bariatric procedures) exhibit comparable improved glucose homeostasis to RYGB [6, 4851].”
BackgroundSalehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323
Janssen, S., Laermans, J., Verhulst, P.-J., Thijs, T., Tack, J., & Depoortere, I. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011508108 · Cited by 317 · cited 1×
“In addition, ghrelin secretion and octanoylation induced by bitter taste receptor agonists is attenuated and glucose-dependent insulinotropic polypeptide secretion occurs earlier in response to glucose in α-Gust / mice compared to wild-type [25,28,29].”
BackgroundSarwer, D. B., Wadden, T. A., Moore, R. H., Baker, A. W., Gibbons, L. M., Raper, S. E., & Williams, N. N. (2008) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2008.04.013 · Cited by 286
Rapid improvement in diabetes after gastric bypass surgery
Lingvay, I., Guth, E., Islam, A., & Livingston, E. (2013) · Diabetes Care · doi:10.2337/dc12-2316 · Cited by 116
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“…studies in humans, a functional GLP-1R is not required for weight loss or improved glucose tolerance after experimental RYGB or VSG in Glp1r / mice or in wild-type mice chronically treated with i.c.v. infusion of exendin(9–39) (Mokadem et al., 2014; Wilson-Pérez et al., 2013; Ye et al., 2014).”
BackgroundSelf-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Treatment of Obesity with Celastrol
Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015) · Cell · doi:10.1016/j.cell.2015.05.011 · Cited by 726
“The effect of Celastrol is more potent than reported for bariatric surgery in mice, with which weight loss is around 35%–40% (Liou et al., 2013; Mokadem et al., 2014; Ryan et al., 2014).”
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Metadata
- Authors
- Mokadem, M., Zechner, J. F., Margolskee, R. F., Drucker, D. J., & Aguirre, V.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 3
- Issue
- 2
- Pages
- 191-201
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W2109164644
- Cited by
- 174
- References
- 12
- FWCI
- 17.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.